- Sepsis is a condition in which the immune response to infection becomes excessive and damages the body. The article explains that it is a major cause of death for children under 5 years old, with about 3 million people dying each year.
- According to the article, when antibiotics alone cannot stop an excessive immune reaction, blood is filtered to remove toxic substances. The company's co-founder and CEO claimed that the Enperon device adsorbs cytokines and endotoxins at the same time.
- The pediatric device Enperon NEO received European CE certification in April this year. According to the article, it is used in intensive care units in 30 countries, including European hospitals, Saudi Arabia, and Thailand.
- The company said it is preparing to apply for approval from the US FDA and aims for annualized revenue of $2 million by the end of 2026. The technology was first developed by scientists at Moscow State University.
The article about the pediatric sepsis device is missing the clinical results data in the original text, which is the first thing that stands out. The adsorption effect and recovery speed seem to be read as the company's claims. It will be worth watching what data is made public during the FDA approval application process.